Skip to main content
SpringerLink
Log in

Association between FGF20 rs12720208 gene polymorphism and Parkinson’s disease: a meta-analysis

  • Original Article
  • Published:
Neurological Sciences Aims and scope Submit manuscript

Abstract

Previous studies have claimed the association of rs12720208 polymorphism in the fibroblast growth factor 20 (FGF20) gene with the increased risk of Parkinson’s disease (PD), but results from the published data were controversial. The aim of our present meta-analysis was to estimate the overall association between FGF20 rs12720208 polymorphism and the risk of PD. Case–control studies with sufficient data evaluating the association between rs12720208 C/T polymorphism and PD susceptibility were systematically identified in PubMed, OVID, SinoMed, Chinese National Knowledge Infrastructure (CNKI) up to July 10, 2015. A total of 3402 PD patients and 3739 controls from seven case–control studies were collected for this meta-analysis. The pooled odds ratio (OR) with its 95 % confidence interval (CI) was calculated to assess the genetic association between FGF20 rs12720208 polymorphism and the risk of PD. In this study, no enough proof was found to prove the association in any genetic models with random-effects model (CT+TT vs. CC: OR = 1.147, 95 % CI: 0.883–1.489, P = 0.304; TT vs. CC+CT: OR = 1.754, 95 % CI: 0.878–3.505, P = 0.112; T vs. C: OR = 1.169, 95 % CI = 0.919–1.487, P = 0.204; TT+CC vs. CT: OR = 0.906, 95 % CI = 0.694–1.182, P = 0.466). Our results suggest that there is no sufficient evidence to support the association between rs12720208 polymorphism and PD risk. Studies with larger sample size across diverse populations and subgroup analyses are necessary in the future.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Thenganatt MA, Jankovic J (2014) Parkinson disease subtypes. JAMA neurol 71(4):499–504

    Article  PubMed  Google Scholar 

  2. Wider C, Ross OA, Wszolek ZK (2010) Genetics of Parkinson disease and essential tremor. Curr Opin Neurol 23(4):388–393

    PubMed  PubMed Central  Google Scholar 

  3. Lin MK, Farrer MJ (2014) Genetics and genomics of Parkinson’s disease. Genome Med 6(6):48

    Article  PubMed  PubMed Central  Google Scholar 

  4. Nalls MA, Pankratz N, Lill CM et al (2014) Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson’s disease. Nat Genet 46(9):989–993

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. van der Walt JM, Noureddine MA, Kittappa R et al (2004) Fibroblast growth factor 20 polymorphisms and haplotypes strongly influence risk of Parkinson disease. Am J Hum Genet 74(6):1121–1127

    Article  PubMed  PubMed Central  Google Scholar 

  6. Ohmachi S, Watanabe Y, Mikami T et al (2000) FGF-20, a novel neurotrophic factor, preferentially expressed in the substantia nigra pars compacta of rat brain. Biochem Biophys Res Commun 277(2):355–360

    Article  CAS  PubMed  Google Scholar 

  7. Ohmachi S, Mikami T, Konishi M et al (2003) Preferential neurotrophic activity of fibroblast growth factor-20 for dopaminergic neurons through fibroblast growth factor receptor-1c. J Neurosci Res 72(4):436–443

    Article  CAS  PubMed  Google Scholar 

  8. Scott WK, Nance MA, Watts RL et al (2001) Complete genomic screen in Parkinson disease: evidence for multiple genes. JAMA 286(18):2239–2244

    Article  CAS  PubMed  Google Scholar 

  9. Kirikoshi H, Sagara N, Saitoh T et al (2000) Molecular cloning and characterization of human FGF-20 on chromosome 8p21.3–p22. Biochem Biophys Res Commun 274(2):337–343

    Article  CAS  PubMed  Google Scholar 

  10. Wang G, van der Walt JM, Mayhew G et al (2008) Variation in the miRNA-433 binding site of FGF20 confers risk for Parkinson disease by overexpression of alpha-synuclein. Am J Hum Genet 82(2):283–289

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Lucking CB, Brice A (2000) Alpha-synuclein and Parkinson’s disease. Cell Mol Life Sci 57(13–14):1894–1908

    Article  CAS  PubMed  Google Scholar 

  12. Clarimon J, Xiromerisiou G, Eerola J et al (2005) Lack of evidence for a genetic association between FGF20 and Parkinson’s disease in Finnish and Greek patients. BMC Neurol 5:11

    Article  PubMed  PubMed Central  Google Scholar 

  13. Wider C, Dachsel JC, Soto AI et al (2009) FGF20 and Parkinson’s disease: no evidence of association or pathogenicity via alpha-synuclein expression. Mov Disord 24:455–459

    Article  PubMed  PubMed Central  Google Scholar 

  14. Ustinova VV, Shadrina MI, Fedotova E et al (2012) Analysis of the rs12720208 single-nucleotide polymorphism of the FGF20 gene in Russian patients with sporadic Parkinson’s disease. Genetika 48(12):1437–1439

    CAS  PubMed  Google Scholar 

  15. Pan J, Li H, Wang Y et al (2012) Fibroblast growth factor 20 (FGF20) polymorphism is a risk factor for Parkinson’s disease in Chinese population. Parkinsonism Relat Disord 18(5):629–631

    Article  PubMed  Google Scholar 

  16. Xu X, Wang N, Xu H et al (2013) Fibroblast growth factor 20 polymorphism in sporadic Parkinson’s disease in Northern Han Chinese. J Clin Neurosci 20(11):1588–1590

    Article  CAS  PubMed  Google Scholar 

  17. de Mena L, Cardo LF, Coto E et al (2010) FGF20 rs12720208 SNP and microRNA-433 variation: no association with Parkinson’s disease in Spanish patients. Neurosci Lett 479(1):22–25

    Article  PubMed  Google Scholar 

  18. Haghnejad L, Emamalizadeh B, Jamshidi J et al (2015) Variation in the miRNA-433 binding site of FGF20 is a risk factor for Parkinson’s disease in Iranian population. J Neurol Sci 355(1–2):72–74

    Article  CAS  PubMed  Google Scholar 

  19. Harbord RM, Egger M, Sterne JA (2006) A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints. Stat Med 25(20):3443–3457

    Article  PubMed  Google Scholar 

  20. Satake W, Mizuta I, Suzuki S et al (2007) Fibroblast growth factor 20 gene and Parkinson’s disease in the Japanese population. Neuro Report 18(9):937–940

    CAS  Google Scholar 

  21. Lei Y, Qi Z, Mou W et al (2014) Correlation analysis between single nucleotide polymorphisms of fibroblast growth factor 20 (FGF20) gene and Parkinson disease. Med J Chin PLA 39(2):129–132

    CAS  Google Scholar 

  22. de Lau LM, Breteler MM (2006) Epidemiology of Parkinson’s disease. Lancet Neurol 5(6):525–535

    Article  PubMed  Google Scholar 

  23. Lesnick TG, Papapetropoulos S, Mash DC et al (2007) A genomic pathway approach to a complex disease: axon guidance and Parkinson disease. PLoS Genet 3(6):e98

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

This work was supported by the grants from the Social Development Project of Jiangsu Province (BE2015721) and “Six Talent Peak” Foundation of Jiangsu Province (2010-WS-030) for Meijiang Feng.

Author information

Authors and Affiliations

  1. Department of Geriatrics, The Second Affiliated Hospital, Nanjing Medical University, No. 121 Jiangjia Yuan Road, Nanjing, 210011, Jiangsu Province, People’s Republic of China

    Xianjing Zhao, Can Zhao & Meijiang Feng

  2. Department of Neurology, The Second Affiliated Hospital, Nanjing Medical University, Nanjing, 210011, People’s Republic of China

    Yanfeng Wu

Authors
  1. Xianjing Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yanfeng Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Can Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Meijiang Feng
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Meijiang Feng.

Ethics declarations

Conflict of interest

The authors declare no conflicts of interest.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplemental Fig. 1

Forest plot on the association between Fibroblast growth factor 20 rs12720208 gene polymorphism and Parkinson’s disease risk under four different comparison models (a-d). a. Dominant model (CT+TT vs. CC). b. Recessive model (TT vs. CC+CT). c. Allele model (T vs. C). d. Over-dominant model (TT+CC vs. CT). (TIFF 8050 kb)

Supplemental Fig. 2

Forest plot of the subgroup meta-analysis (based on the region) for an association between Fibroblast growth factor 20 rs12720208 gene polymorphism and Parkinson’s disease risk under four different comparison models (a-d). a. Dominant model (CT+TT vs. CC). b. Recessive model (TT vs. CC+CT). c. Allele model (T vs. C). d. Over-dominant model (TT+CC vs. CT). (TIFF 11982 kb)

Supplemental Fig. 3

Forest plot of the subgroup meta-analysis (based on the sample size) for an association between Fibroblast growth factor 20 rs12720208 gene polymorphism and Parkinson’s disease risk under four different comparison models (a-d). a. Dominant model (CT+TT vs. CC). b. Recessive model (TT vs. CC+CT). c. Allele model (T vs. C). d. Over-dominant model (TT+CC vs. CT). (TIFF 10079 kb)

Supplemental Fig. 4

Funnel plot for studies investigating the effect of fibroblast growth factor 20 gene rs12720208 polymorphism on the risk of Parkinson’s disease. (TIFF 1124 kb)

Supplementary material 5 (DOCX 16 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zhao, X., Wu, Y., Zhao, C. et al. Association between FGF20 rs12720208 gene polymorphism and Parkinson’s disease: a meta-analysis. Neurol Sci 37, 1119–1126 (2016). https://doi.org/10.1007/s10072-016-2559-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10072-016-2559-0

Keywords

Search

Navigation